Become a Founding Member for $999 a year, locked for life

    Claim a seat
    MavenlyMavenly

    § Federal grant opportunity · PAR-28-043

    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development

    National Institutes of Health is accepting applications for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development. The deadline is Rolling / not published and the published award range is Award amount not published.

    Key facts

    Funder
    National Institutes of Health
    Application deadline
    Rolling / not published
    Award range
    Award amount not published
    Eligibility
    county governments, nonprofits non higher education with 501c3, state governments, city or township governments, small businesses, private institutions of higher education, public and indian housing authorities, other, special district governments, other native american tribal organizations, public and state institutions of higher education, for profit organizations other than small businesses, independent school districts, federally recognized native american tribal governments, nonprofits non higher education without 501c3
    Geography
    United States
    Focus areas
    Health
    Opportunity number
    PAR-28-043

    Program overview

    The NIH Blueprint for Neuroscience Research is interested in continuing to support the B lue P rint N eurotherapeutics Network for S mall M olecules (BPN-SM)- a program designed to help investigators advance promising small-molecule therapeutics toward clinical testing. The BPN-SM program supports drug discovery and development activities in investigators’ own laboratories while also providing access to NIH-supported subject matter experts and contract research organizations (CROs) with capabilities in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. By integrating NIH resources with industry-standard expertise, BPN-SM advances investigator-initiated drug discovery while enabling investigators to retain and strengthen their intellectual property while gaining hands-on experience in translational drug development. The overarching goal of the program is to reduce the risk of scientific and therapy development sufficiently to enable external partners to take on late-stage development and ultimately bring new therapies to patients. In addition, this BPN program is specifically focused on small molecules and excludes biologics, because development, regulatory, and manufacturing considerations for each class of therapeutics differ substantially from each other. It will use a phased cooperative agreement mechanism which will enable the program to support innovative but higher-risk projects, with decisions of continued support being contingent on demonstrated feasibility of yearly milestones. A cooperative agreement framework is proposed because several key aspects of the program will involve collaborative activities between the investigators and NIH program staff, with substantial involvement beyond the normal scope of grant stewardship. The project principal investigator(s) and NIH program staff will work jointly with NIH-supported subject matter experts to coordinate and participate in all scientific and technical management aspects of the project. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop competitive projects and establish the cross-disciplinary collaborations necessary for success.

    How to apply

    1. Confirm your organization meets the eligibility criteria above.
    2. Read the full funding opportunity announcement from National Institutes of Health.
    3. Draft your narrative against the funder's stated priorities and review criteria.
    4. Submit before Rolling / not published, allowing time for registration and validation.

    View the official funding announcement

    Find every grant your organization qualifies for

    Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.